Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment

Dow Jones

Yesterday

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website.

In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company's lead program, Ampligen$(R)$ (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca's Imfinzi(R) (durvalumab).

The CEO Corner segment is now available here.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen(R) (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact: 
 
JTC Team, LLC 
Jenene Thomas 
908.824.0775 
AIM@jtcir.com

(END) Dow Jones Newswires

December 10, 2025 09:00 ET (14:00 GMT)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2590862538"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590862538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590862538?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590862538","market":"sh","top_or_hot":-1,"title":"Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/AIM\">AIM ImmunoTech Inc.</a> (NYSE American: AIM) (\"AIM\" or the \"Company\") today announced the next CEO Corner segment has been published on the Company's website. \n</p>\n<p>\n     In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company's lead program, Ampligen<a href=\"https://laohu8.com/S/R\">$(R)$</a> (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca's Imfinzi(R) (durvalumab). \n</p>\n<p>\n     The CEO Corner segment is now available here. \n</p>\n<p>\n     About AIM ImmunoTech Inc. \n</p>\n<p>\n     AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen(R) (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. \n</p>\n<p>\n     For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and <a href=\"https://laohu8.com/S/META\">Facebook</a>. \n</p>\n<pre style=\"white-space: pre\">\nInvestor Contact: \n \nJTC Team, LLC \nJenene Thomas \n908.824.0775 \nAIM@jtcir.com \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2025 09:00 ET (14:00 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: AIM ImmunoTech Announces Release of the Next CEO Corner Segment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-10 22:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/AIM\">AIM ImmunoTech Inc.</a> (NYSE American: AIM) (\"AIM\" or the \"Company\") today announced the next CEO Corner segment has been published on the Company's website. \n</p>\n<p>\n     In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company's lead program, Ampligen<a href=\"https://laohu8.com/S/R\">$(R)$</a> (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca's Imfinzi(R) (durvalumab). \n</p>\n<p>\n     The CEO Corner segment is now available here. \n</p>\n<p>\n     About AIM ImmunoTech Inc. \n</p>\n<p>\n     AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen(R) (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. \n</p>\n<p>\n     For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and <a href=\"https://laohu8.com/S/META\">Facebook</a>. \n</p>\n<pre style=\"white-space: pre\">\nInvestor Contact: \n \nJTC Team, LLC \nJenene Thomas \n908.824.0775 \nAIM@jtcir.com \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 10, 2025 09:00 ET (14:00 GMT)\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"R","symbol_name":"瑞德系统","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2590862538","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590862538","pubTimestamp":1765375200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"OCALA, Fla., Dec. 10, 2025  -- AIM ImmunoTech Inc.   today announced the next CEO Corner segment has been published on the Company's website.In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company's lead program, Ampligen , and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca's Imfinzi .The CEO Corner segment is now available here.AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen , a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.For more information, please visit aimimmuno.com and connect wit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"R":"瑞德系统","BK4139":"生物科技","BK4232":"货物陆运","BK4557":"大麻股","BK4022":"陆运","AIM":"AIM ImmunoTech Inc."},"translate_title":"新闻稿：AIM ImmunoTech宣布发布下一个CEO角部分","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"R":1,"AIM":1.5},"content_text":"OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (\"AIM\" or the \"Company\") today announced the next CEO Corner segment has been published on the Company's website. \n\n\n     In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company's lead program, Ampligen$(R)$ (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b/2 clinical trial in combination with AstraZeneca's Imfinzi(R) (durvalumab). \n\n\n     The CEO Corner segment is now available here. \n\n\n     About AIM ImmunoTech Inc. \n\n\n     AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen(R) (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. \n\n\n     For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. \n\n\nInvestor Contact: \n \nJTC Team, LLC \nJenene Thomas \n908.824.0775 \nAIM@jtcir.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 09:00 ET (14:00 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}